In particular, the JAK1/2 inhibitor ruxolitinib appears to be a suitable candidate for reducing the concurrent need for glucocorticoids in VEXAS syndrome patients, whether or not they have myeloid neoplasia [9]. Here, JAK1 is linked to VEXAS syndrome.